Home PR Newswire
Friday, March 6, 2026
21.3
C
Bengaluru
Hot topics
Making Peace with an Unlived Life – My Journey by Deep Bhandari
The Beginning
I was at crossroads after completing computer...
Indian Pharma November Sales: What Do They Say?
IQVIA's Market Feedback Report (MFR) and PharmaTrac's Acquaint report...
Indian Pharma’s November 2025: How GLP-1s Rewired the Market
Indian pharma wrapped up November 2025 with serious velocity....
Is America’s “Miracle Shot” Worth the Hype and Risk? A Verified Look at the Claims
Introduction:An email circulating from Visibility Nexus references America’s “hottest...
Analysis of the Fastest Growing Companies and Therapy Areas in IPM – MAT Dec’24
Growth Performance of Top 50 Companies in IPM (MAT...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
Hot topics
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
DiME (Digi MarketEr):-TiME to SHiNE
The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.
Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future
For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
Breaking Performance Barriers
Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai
A Cardiologist Recounts his Fightback from a Near Death Covid19 Infection
In the lockdown, while I was on regular OPD and ICU rounds at a COVID hospital, I started noticing some mild symptoms of the Coronavirus infection. Being in the medical field and considering the severity of the pandemic situation then, I was very careful and cautious, and observed the symptoms closely. The symptoms persisted and I had to self-quarantine until the medical test reports came. It was important for me to isolate myself from the rest of the medical team and prevent the spread of the virus. Finally, the report came: I was COVID positive!
Stunned and slightly devastated; I broke the news to my family who could not believe it either. As a doctor, I could only treat, comfort and empathize with the COVID patients undergoing treatment; completely isolated from their loved ones. But now, I could actually feel the uncertainty of the situation. I was hospitalized and continued to experience body-ache during the admission. It was a stressful situation where I felt anxious and stressed about everything.
My CT scan reports showed mild lung infection on the day of admission but as the cytokines storm developed, my lungs were 76 % damaged in 3-5 days and I was short of breath and my oxygen level deteriorated to less than 80. I was shifted to an ICU with high-flow oxygen and was on a BiPap machine which I had purchased a few weeks ago for the hospital and never imagined that I would be using myself one day.
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Newsletter
Get important news delivered directly to your inbox and stay connected!